Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality (Q41653534)

6 October 2017

1 reference

title

Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality (English)

1 reference

6 October 2017

0 references

Habib G

1

1 reference

6 October 2017

language of work or name

1 reference

1 January 1997

1 reference

6 October 2017

published in

Clinical Therapeutics

1 reference

6 October 2017

volume

19 Suppl A

1 reference

6 October 2017

page(s)

39-52

1 reference

Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

The multifactor primary prevention trial in Göteborg, Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Influence of heart rate on mortality after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Influence of heart rate on mortality among persons with hypertension: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Trends in acute myocardial infarction and coronary heart disease death in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Heart rate variability during the acute phase of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Retarding effect of lowered heart rate on coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

The effects of heart rate, myocardial ischemia and vagal stimulation on the threshold for ventricular fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Use of atropine in patients with acute myocardial infarction and sinus bradycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Deleterious effects of increased heart rate on infarct size in the conscious dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Prediction of cardiovascular deaths and non-fatal reinfarctions after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Reduction of Infarct Size with the Early Use of Timolol in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Heart rate and cardiovascular mortality: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

A long-term prevention study with oxprenolol in coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Long‐Term Survival and Use of Antihypertensive Medications in Older Persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina Pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

Selective inhibition of T-type Ca2+ channels by Ro 40-5967

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980036-7

7 January 2021

10.1016/S0149-2918(97)80036-7

Identifiers

DOI

1 reference

6 October 2017

1 reference